Institut Jantung Negara (IJN) has successfully performed Southeast Asia’s first transradial renal denervation (RDN) procedure using the Iberis® RDN System, marking a new milestone in the treatment of resistant hypertension.
The procedure was carried out on a 35-year-old patient whose blood pressure remained uncontrolled despite optimal multi-drug therapy. It was led by Senior Consultant Cardiologist Dato’ Sri Dr. Azhari Rosman together with Consultant Cardiologist Dr. Thum Chan Ho.
Renal denervation is a minimally invasive procedure that targets nerves surrounding the renal arteries to help regulate blood pressure in selected patients with resistant hypertension.
Unlike the traditional femoral approach via the groin, the transradial technique is performed through the radial artery in the wrist. IJN said this method may improve patient comfort, allow earlier mobilisation and reduce access-related complications in suitable patients.
The Iberis® RDN System used in the procedure delivers radiofrequency energy to renal sympathetic nerves and includes safety features such as continuous monitoring and automatic controls.
Dato’ Sri Dr. Azhari Rosman said the procedure represents an important advancement in treatment options for selected patients.
“Resistant hypertension remains a complex condition that requires careful evaluation and a personalised treatment approach. Renal denervation provides an additional option for selected patients whose blood pressure remains uncontrolled despite optimal medical therapy,” he said.
“By performing the procedure through the radial artery, we are able to offer a less invasive access route that may improve patient comfort and support earlier mobilisation. This milestone reflects IJN’s ongoing efforts to bring advanced, evidence-based treatment options closer to patients who may benefit from them,” he added.
IJN Group Chief Executive Officer Prof. Datuk Seri Dr. Mohamed Ezani Md Taib said the achievement reflects the hospital’s continued focus on innovation in cardiovascular care.
“Hypertension remains one of the most important risk factors for cardiovascular disease, and resistant hypertension can be particularly challenging to manage. This milestone demonstrates IJN’s ongoing commitment to exploring advanced treatment options that may benefit patients who require additional therapeutic approaches beyond medication,” he said.
IJN said the milestone reinforces its role as Malaysia’s national heart centre and a regional leader in cardiovascular innovation.
